HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Fennec Pharmaceuticals (NASDAQ:FENC) but lowered the price target from $18 to $15.

May 15, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. has maintained its Buy rating on Fennec Pharmaceuticals but lowered the price target from $18 to $15.
The Buy rating suggests continued confidence in Fennec Pharmaceuticals' prospects, but the lowered price target indicates a more cautious outlook on its short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100